Browse ALDH1L2

Summary
SymbolALDH1L2
Namealdehyde dehydrogenase 1 family, member L2
Aliases FLJ38508; mtFDH; mitochondrial 10-formyltetrahydrofolate dehydrogenase; 10-formyltetrahydrofolate dehydrogen ......
Chromosomal Location12q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion
Domain PF00171 Aldehyde dehydrogenase family
PF02911 Formyl transferase
PF00551 Formyl transferase
PF00550 Phosphopantetheine attachment site
Function

-

> Gene Ontology
 
Biological Process GO:0006575 cellular modified amino acid metabolic process
GO:0006730 one-carbon metabolic process
GO:0006732 coenzyme metabolic process
GO:0006760 folic acid-containing compound metabolic process
GO:0006766 vitamin metabolic process
GO:0006767 water-soluble vitamin metabolic process
GO:0009109 coenzyme catabolic process
GO:0009256 10-formyltetrahydrofolate metabolic process
GO:0009258 10-formyltetrahydrofolate catabolic process
GO:0009397 folic acid-containing compound catabolic process
GO:0019439 aromatic compound catabolic process
GO:0042219 cellular modified amino acid catabolic process
GO:0042558 pteridine-containing compound metabolic process
GO:0042560 pteridine-containing compound catabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0046653 tetrahydrofolate metabolic process
GO:0046655 folic acid metabolic process
GO:0046700 heterocycle catabolic process
GO:0051186 cofactor metabolic process
GO:0051187 cofactor catabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
Molecular Function GO:0004029 aldehyde dehydrogenase (NAD) activity
GO:0016155 formyltetrahydrofolate dehydrogenase activity
GO:0016620 oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor
GO:0016645 oxidoreductase activity, acting on the CH-NH group of donors
GO:0016646 oxidoreductase activity, acting on the CH-NH group of donors, NAD or NADP as acceptor
GO:0016741 transferase activity, transferring one-carbon groups
GO:0016742 hydroxymethyl-, formyl- and related transferase activity
GO:0016903 oxidoreductase activity, acting on the aldehyde or oxo group of donors
GO:0019145 aminobutyraldehyde dehydrogenase activity
GO:0047105 4-trimethylammoniobutyraldehyde dehydrogenase activity
Cellular Component GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG hsa00670 One carbon pool by folate
Reactome R-HSA-1430728: Metabolism
R-HSA-196757: Metabolism of folate and pterines
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
Summary
SymbolALDH1L2
Namealdehyde dehydrogenase 1 family, member L2
Aliases FLJ38508; mtFDH; mitochondrial 10-formyltetrahydrofolate dehydrogenase; 10-formyltetrahydrofolate dehydrogen ......
Chromosomal Location12q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ALDH1L2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolALDH1L2
Namealdehyde dehydrogenase 1 family, member L2
Aliases FLJ38508; mtFDH; mitochondrial 10-formyltetrahydrofolate dehydrogenase; 10-formyltetrahydrofolate dehydrogen ......
Chromosomal Location12q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ALDH1L2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolALDH1L2
Namealdehyde dehydrogenase 1 family, member L2
Aliases FLJ38508; mtFDH; mitochondrial 10-formyltetrahydrofolate dehydrogenase; 10-formyltetrahydrofolate dehydrogen ......
Chromosomal Location12q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ALDH1L2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.5478.22e-05
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.7590.0454
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.390.0451
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.7020.0307
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7070.662
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6960.734
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0150.98
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1610.911
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2690.871
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4970.577
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8260.093
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0970.658
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ALDH1L2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.125-13.90.621
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472528.6-3.61
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolALDH1L2
Namealdehyde dehydrogenase 1 family, member L2
Aliases FLJ38508; mtFDH; mitochondrial 10-formyltetrahydrofolate dehydrogenase; 10-formyltetrahydrofolate dehydrogen ......
Chromosomal Location12q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ALDH1L2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolALDH1L2
Namealdehyde dehydrogenase 1 family, member L2
Aliases FLJ38508; mtFDH; mitochondrial 10-formyltetrahydrofolate dehydrogenase; 10-formyltetrahydrofolate dehydrogen ......
Chromosomal Location12q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ALDH1L2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ALDH1L2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolALDH1L2
Namealdehyde dehydrogenase 1 family, member L2
Aliases FLJ38508; mtFDH; mitochondrial 10-formyltetrahydrofolate dehydrogenase; 10-formyltetrahydrofolate dehydrogen ......
Chromosomal Location12q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ALDH1L2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolALDH1L2
Namealdehyde dehydrogenase 1 family, member L2
Aliases FLJ38508; mtFDH; mitochondrial 10-formyltetrahydrofolate dehydrogenase; 10-formyltetrahydrofolate dehydrogen ......
Chromosomal Location12q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ALDH1L2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolALDH1L2
Namealdehyde dehydrogenase 1 family, member L2
Aliases FLJ38508; mtFDH; mitochondrial 10-formyltetrahydrofolate dehydrogenase; 10-formyltetrahydrofolate dehydrogen ......
Chromosomal Location12q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ALDH1L2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolALDH1L2
Namealdehyde dehydrogenase 1 family, member L2
Aliases FLJ38508; mtFDH; mitochondrial 10-formyltetrahydrofolate dehydrogenase; 10-formyltetrahydrofolate dehydrogen ......
Chromosomal Location12q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ALDH1L2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.